Introduction & Directions

 
33% of survey complete.

Tumor mutational burden (TMB) is an emerging biomarker that measures the extent of somatic mutation within a tumor to estimate the neo-antigenic burden, thereby providing a probabilistic measure of a patient’s response to immunotherapy based on their likelihood of expressing a sufficient number of immune reactive neo-antigens. Determination of TMB with molecular methods is currently being utilized, however best practice recommendations are needed to effectively shepherd this into clinical practice. AMP has convened a working group with representation from American Society for Clinical Oncology (ASCO), College of American Pathologists (CAP), and Society for Immunotherapy of Cancer (SITC) to assess current clinical practice and provide evidence-based subject matter expert recommendations regarding best practices and performance characteristics of clinical TMB molecular methods.

This survey is open to both AMP members and non-members, so please share the survey link with your colleagues as needed. The survey is designed to capture individual responses from molecular professionals either currently performing or considering performing TMB testing as a clinical service in their laboratories. If your organization or company would like to provide feedback on the survey please contact Robyn directly at rtemple@amp.org.

T